WO2002058724A8 - Utilisation de lp82 pour traiter les problemes de poids - Google Patents

Utilisation de lp82 pour traiter les problemes de poids

Info

Publication number
WO2002058724A8
WO2002058724A8 PCT/US2002/000498 US0200498W WO02058724A8 WO 2002058724 A8 WO2002058724 A8 WO 2002058724A8 US 0200498 W US0200498 W US 0200498W WO 02058724 A8 WO02058724 A8 WO 02058724A8
Authority
WO
WIPO (PCT)
Prior art keywords
body weight
weight disorders
treat body
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/000498
Other languages
English (en)
Other versions
WO2002058724A3 (fr
WO2002058724A2 (fr
Inventor
Niles Wayne Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to EP02720768A priority Critical patent/EP1390060A2/fr
Priority to US10/466,695 priority patent/US20040162237A1/en
Publication of WO2002058724A2 publication Critical patent/WO2002058724A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002058724A3 publication Critical patent/WO2002058724A3/fr
Publication of WO2002058724A8 publication Critical patent/WO2002058724A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

L'invention porte sur un gène de mammifère intervenant dans le traitement des problèmes de poids, et plus spécifiquement sur les procédés d'utilisation de compositions à base de polynucléotides LP82, de polypeptides LP82, et/ou d'anticorps LP82, en vue de la prévention et/ou du traitement chez les mammifères de problèmes de poids, dont l'obésité, la cachexie, et l'anorexie.
PCT/US2002/000498 2001-01-26 2002-01-15 Utilisation de lp82 pour traiter les problemes de poids Ceased WO2002058724A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02720768A EP1390060A2 (fr) 2001-01-26 2002-01-15 Utilisation de lp82 pour traiter les problemes de poids
US10/466,695 US20040162237A1 (en) 2002-01-15 2002-01-15 Use of lp82 to treat body weight disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26423901P 2001-01-26 2001-01-26
US60/264,239 2001-01-26

Publications (3)

Publication Number Publication Date
WO2002058724A2 WO2002058724A2 (fr) 2002-08-01
WO2002058724A3 WO2002058724A3 (fr) 2003-12-18
WO2002058724A8 true WO2002058724A8 (fr) 2004-05-21

Family

ID=23005167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000498 Ceased WO2002058724A2 (fr) 2001-01-26 2002-01-15 Utilisation de lp82 pour traiter les problemes de poids

Country Status (2)

Country Link
EP (1) EP1390060A2 (fr)
WO (1) WO2002058724A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123998T2 (de) 2000-08-08 2007-09-06 Zymogenetics, Inc., Seattle Lösliche zcyctor 11 cytokinrezeptoren
ATE333888T1 (de) 2000-09-15 2006-08-15 Zymogenetics Inc Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
CA2467723C (fr) 2001-12-17 2011-09-27 Zymogenetics, Inc. Methode de traitement du cancer du col de l'uterus
JP2007525438A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
WO2005014028A1 (fr) * 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukine-20 dans le traitement et le diagnostic des etats associes a la neovascularisation
WO2005052001A2 (fr) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anticorps du recepteur anti-il-20 et partenaires de liaison et procedes d'utilisation dans l'inflammation
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
IL136076A0 (en) * 1997-11-26 2001-05-20 Zymogenetics Inc Mammalian cytokin-like polypeptide -10

Also Published As

Publication number Publication date
WO2002058724A3 (fr) 2003-12-18
WO2002058724A2 (fr) 2002-08-01
EP1390060A2 (fr) 2004-02-25

Similar Documents

Publication Publication Date Title
IL160524A0 (en) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity
WO2001083729A3 (fr) Vecteurs pour transduction oculaire et utilisation en therapie genique
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
HK1038755A1 (zh) Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症
WO2005103041A3 (fr) Traitement des troubles du systeme nerveux central au moyen de modulateurs cibles du snc
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
WO2004032877A3 (fr) Compositions, organismes et methodologies utilisant une nouvelle kinase humaine
CA2474510A1 (fr) Heterocycles tricycliques fusionnes utilises dans le traitement de troubles hyperproliferatifs
WO2002058724A8 (fr) Utilisation de lp82 pour traiter les problemes de poids
WO2003033557A3 (fr) Copolymeres fluores, leur production et leur utilisation
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2002039997A3 (fr) Composes modulant ace-2 et procedes d'utilisation associes
WO2005112903A3 (fr) Utilisation d'antagonistes de la ghrelin pour le traitement de certaines maladies du systeme nerveux central
AU2002315485A1 (en) Compositions and methods for the treatment of body weight disorders, including obesity
WO2004091646A3 (fr) Compositions de slurp-1 et leurs methodes d'utilisation
WO2006028492A3 (fr) Hc1q/tnf7 et ses utilisations
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
WO2002060382A3 (fr) Composes et utilisations
AU2002365621A1 (en) Composition for treating the surface of the skin
WO2002068614A3 (fr) Protéine du facteur régulateur de l'interféron-1/de fusion réceptrice d'oestrogene humain et son utilisation dans le traitement des carcinomes
WO2003033534A3 (fr) Polynucleotides et polypeptides ngzipa, ngzipd, pgzipa et pgzipd et utilisations de ceux-ci
ZA200302911B (en) Method and composition for treatment of ocular hypertension and glaucoma.
AU2003290560A1 (en) Inmould process for the spheroidization and inoculation treatment of cast sg iron
WO2003029414A3 (fr) Introduction du gene wlds pour la prevention de la degenerescence axonale dans les maladies neurologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10466695

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002720768

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002720768

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWW Wipo information: withdrawn in national office

Ref document number: 2002720768

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP